.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,674,895

« Back to Dashboard

Claims for Patent: 5,674,895

Title: Dosage form comprising oxybutynin
Abstract:A composition comprising oxybutynin and a device comprising oxybutynin are disclosed for oxybutynin therapy.
Inventor(s): Guittard; George V. (Cupertino, CA), Jao; Francisco (San Jose, CA), Marks; Susan M. (San Jose, CA), Kidney; David J. (Sunnyvale, CA), Gumucio; Fernando (Santa Clara, CA)
Assignee: Alza Corporation (Palo Alto, CA)
Application Number:08/445,849
Patent Claims: 1. A therapeutic composition comprising: 1 ng to 450 mg of oxybutynin, 40 mg to 250 mg of polyalkylene oxide, 1 mg to 25 mg of hydroxypropylalkylcellulose, and 0.01 mg to 5 mg of a lubricant.

2. The therapeutic composition according to claim 1, wherein the oxybutynin is a therapeutically acceptable salt selected from the group consisting of acetate, bitartrate, citrate, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, hydrobromide, hydrochloride, lactate, malate, maleate, mandelate, mesylate, methylnitrate, mucate, napsylate, nitrate, pamoate, pantothenate, phosphate, salicylate, stearate, succinate, sulfate, tannate, and tartrate.

3. A bilayered tablet comprising a therapeutic layer comprising 1 ng to 450 mg of oxybutynin, 40 mg to 450 mg of polyalkylene oxide, 1 mg to 25 mg of hydroxypropylalkylcellulose and 0.01 mg to 5 mg of a lubricant; in contact with a hydrogel layer comprising 40 mg to 250 mg of polyalkylene oxide, 10 mg to 50 mg of an osmagent, 0.1 mg to 20 mg of hydroxypropylalkylcellulose, 0.0 ng to 1.5 mg of an antioxidant, and 0.2 mg to 7 mg of a lubricant.

4. A bilayered tablet comprising a therapeutic layer comprising a therapeutic layer comprising 1 ng to 450 mg of oxybutynin, 40 mg to 250 mg of polyalkylene oxide, 1 mg to 25 mg of hydroxypropylalkylcellulose, and 0.01 mg to 5 mg of a lubricant; said layer in contact with a push layer comprising 40 mg to 250 mg of an alkali carboxymethylcellulose, 10 mg to 50 mg of an osmagent, 0.1 mg to 20 mg of hydroxypropylalkylcellulose, 0.1 mg to 30 mg of hydroxyalkylcellulose, 0.0 ng to 1.5 mg of an antioxidant, and 0.2 mg to 7 mg of a lubricant.

5. A delivery device for administering oxybutynin to a patient in need of oxybutynin, wherein the delivery device comprises: a layer comprising 1 ng to 450 mg of oxybutynin, 40 mg to 250 mg of polyalkylene oxide, 1 mg to 25 mg of hydroxypropylalkylcellulose, and 1 mg to 50 mg of an osmagent; and contacting layer comprising 40 mg to 250 mg of an osmopolymer and 10 mg to 50 mg of an osmagent; a semipermeable wall that surrounds the layers, which semipermeable wall is permeable to the passage of fluid, and impermeable to the passage of oxybutynin, and an exit through the semipermeable wall for administering the oxybutynin to the patient at a controlled rate over time.

6. A delivery device for administering oxybutynin to a patient in need of oxybutynin, wherein the delivery device comprises: a drug layer comprising 1 ng to 450 mg of oxybutynin, 40 mg to 250 mg of polyalkylene oxide, 1 mg to 25 mg of hydroxypropylalkylcellulose, 1 mg to 50 mg of an osmagent; and a contacting displacement layer comprising 40 mg to 250 mg of carboxymethylcellulose and 10 mg to 50 mg of an osmagent; a semipermeable wall that surrounds the layers, which semipermeable wall is permeable to the passage of fluid, and impermeable to the passage of oxybutynin, and an exit through the semipermeable wall for administering the oxybutynin to the patient at a controlled rate over time.

7. A delivery device for administering oxybutynin to a patient in need of oxybutynin, wherein the delivery device comprises: a drug layer comprising 1 ng to 450 mg of oxybutynin, 40 mg to 250 mg of polyalkylene oxide, 1 mg to 25 mg of a hydroxypropylalkylcellulose, 1 mg to 50 mg of an osmagent; and a contracting displacement layer comprising 40 mg to 250 mg of polyalkylene oxide, and 10 mg to 50 mg of an osmagent; a semipermeable wall that surrounds the layer, which semipermeable wall is permeable to the passage of fluid, and impermeable to the passage of oxybutynin, and an exit through the semipermeable wall for administering the oxybutynin to the patient at a controlled rate over time.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc